Flexion to Present New Cost-Effectiveness Data on Zilretta™ (FX006) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting

Findings suggest Zilretta could potentially provide a cost-effective treatment option for patients with osteoarthritis of the knee BURLINGTON, Mass., May 22, 2017 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the findings from a new health economics analysis of Zilretta (also known as FX006), the company’s lead investigational candidate for the treatment of knee […]